Literature DB >> 9026483

Increased production of tumour necrosis factor-alpha interleukin-1 beta, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease.

J M Reimund1, C Wittersheim, S Dumont, C D Muller, J S Kenney, R Baumann, P Poindron, B Duclos.   

Abstract

BACKGROUND: Increasing evidence points to a important role for inflammatory cytokines for the pathogenesis of Crohn's disease. AIM: To compare the secretion rate of tumour necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1 beta) and interleukin-6 (IL-6) by morphologically normal and inflamed intestinal mucosa from patients with Crohn's disease.
RESULTS: Organ cultures of intestinal biopsy specimens taken from areas of affected mucosa from patients with Crohn's disease spontaneously produced increased amounts of TNF-alpha, IL-1 beta, and IL-6 compared with controls but also biopsy specimens taken in macroscopically and microscopically unaffected areas in the same patients. Concentrations of IL-1 beta and IL-6 measured in the supernatant fluid of biopsy cultures were positively correlated with the degree of tissue involvement measured by both endoscopic and histological grading. By contrast, TNF-alpha concentrations were not correlated to endoscopic and histological grading.
CONCLUSIONS: These consistently raised TNF-alpha, IL-1 beta and IL-6 secretions by normal appearing mucosa from patients with Crohn's disease provide evidence for a sustained immune stimulation in Crohn's disease even in the absence of patent inflammation. The results shed a new light on the role of inflammatory cytokines in the onset of intestinal tissue damage in Crohn's disease and suggest that the range of intestinal lesions in Crohn's disease may be wider than suspected on the basis of regular endoscopic and histological examinations.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9026483      PMCID: PMC1383392          DOI: 10.1136/gut.39.5.684

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  28 in total

1.  Tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 expression in inflammatory bowel disease.

Authors:  C Stevens; G Walz; C Singaram; M L Lipman; B Zanker; A Muggia; D Antonioli; M A Peppercorn; T B Strom
Journal:  Dig Dis Sci       Date:  1992-06       Impact factor: 3.199

2.  Impaired response of activated mononuclear phagocytes to interleukin 4 in inflammatory bowel disease.

Authors:  S Schreiber; T Heinig; U Panzer; R Reinking; A Bouchard; P D Stahl; A Raedler
Journal:  Gastroenterology       Date:  1995-01       Impact factor: 22.682

3.  Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease.

Authors:  E J Breese; C A Michie; S W Nicholls; S H Murch; C B Williams; P Domizio; J A Walker-Smith; T T MacDonald
Journal:  Gastroenterology       Date:  1994-06       Impact factor: 22.682

4.  Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease.

Authors:  H C Reinecker; M Steffen; T Witthoeft; I Pflueger; S Schreiber; R P MacDermott; A Raedler
Journal:  Clin Exp Immunol       Date:  1993-10       Impact factor: 4.330

5.  Interleukin-2- and interferon-gamma-secreting T cells in normal and diseased human intestinal mucosa.

Authors:  E Breese; C P Braegger; C J Corrigan; J A Walker-Smith; T T MacDonald
Journal:  Immunology       Date:  1993-01       Impact factor: 7.397

6.  Cytokine messenger RNA profiles in inflammatory bowel disease mucosa detected by polymerase chain reaction amplification.

Authors:  K L Isaacs; R B Sartor; S Haskill
Journal:  Gastroenterology       Date:  1992-11       Impact factor: 22.682

7.  Microscopic activity in ulcerative colitis: what does it mean?

Authors:  S A Riley; V Mani; M J Goodman; S Dutt; M E Herd
Journal:  Gut       Date:  1991-02       Impact factor: 23.059

8.  Enhanced local production of complement components in the small intestines of patients with Crohn's disease.

Authors:  O Ahrenstedt; L Knutson; B Nilsson; K Nilsson-Ekdahl; B Odlind; R Hällgren
Journal:  N Engl J Med       Date:  1990-05-10       Impact factor: 91.245

9.  Use of coculture of colonic mucosal biopsies to investigate the release of eicosanoids by inflamed and uninflamed mucosa from patients with inflammatory bowel disease.

Authors:  T D Wardle; L Hall; L A Turnberg
Journal:  Gut       Date:  1992-12       Impact factor: 23.059

10.  Role of interleukin 1 in inflammatory bowel disease--enhanced production during active disease.

Authors:  M Ligumsky; P L Simon; F Karmeli; D Rachmilewitz
Journal:  Gut       Date:  1990-06       Impact factor: 23.059

View more
  87 in total

1.  Increased production of matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 by inflamed mucosa in inflammatory bowel disease.

Authors:  E Louis; C Ribbens; A Godon; D Franchimont; D De Groote; N Hardy; J Boniver; J Belaiche; M Malaise
Journal:  Clin Exp Immunol       Date:  2000-05       Impact factor: 4.330

2.  IL-1beta and IL-6 excite neurons and suppress nicotinic and noradrenergic neurotransmission in guinea pig enteric nervous system.

Authors:  Y Xia; H Z Hu; S Liu; J Ren; D H Zafirov; J D Wood
Journal:  J Clin Invest       Date:  1999-05       Impact factor: 14.808

3.  Increased mucosal tumour necrosis factor alpha production in Crohn's disease can be downregulated ex vivo by probiotic bacteria.

Authors:  N Borruel; M Carol; F Casellas; M Antolín; F de Lara; E Espín; J Naval; F Guarner; J R Malagelada
Journal:  Gut       Date:  2002-11       Impact factor: 23.059

4.  Cytokine profiles in peripheral blood of children and adults with Crohn disease.

Authors:  Seung Pak; Nina Holland; Elizabeth A Garnett; Elizabeth Mileti; Uma Mahadevan; Rachel Beckert; Bittoo Kanwar; Melvin B Heyman
Journal:  J Pediatr Gastroenterol Nutr       Date:  2012-06       Impact factor: 2.839

5.  Current directions of biologic therapies in inflammatory bowel disease.

Authors:  Catherine Reenaers; Edouard Louis; Jacques Belaiche
Journal:  Therap Adv Gastroenterol       Date:  2010-03       Impact factor: 4.409

6.  Effect of IBD sera on expression of inducible and endothelial nitric oxide synthase in human umbilical vein endothelial cells.

Authors:  Károly Palatka; Zoltán Serfozo; Zoltán Veréb; Róbert Bátori; Beáta Lontay; Zoltán Hargitay; Zoltán Nemes; Miklós Udvardy; Ferenc Erdodi; István Altorjay
Journal:  World J Gastroenterol       Date:  2006-03-21       Impact factor: 5.742

7.  Short chain fatty acids stimulate epithelial mucin 2 expression through differential effects on prostaglandin E(1) and E(2) production by intestinal myofibroblasts.

Authors:  L E M Willemsen; M A Koetsier; S J H van Deventer; E A F van Tol
Journal:  Gut       Date:  2003-10       Impact factor: 23.059

8.  Profile of soluble cytokine receptors in Crohn's disease.

Authors:  T Gustot; A Lemmers; E Louis; C Nicaise; E Quertinmont; J Belaiche; S Roland; A Van Gossum; J Devière; D Franchimont
Journal:  Gut       Date:  2005-04       Impact factor: 23.059

9.  Subclinical intestinal inflammation in patients with Crohn's disease following bowel resection: a smoldering fire.

Authors:  Cesare Ruffolo; Marco Scarpa; Diego Faggian; Daniela Basso; Renata D'Incà; Mario Plebani; Giacomo C Sturniolo; Nicolò Bassi; Imerio Angriman
Journal:  J Gastrointest Surg       Date:  2009-11-10       Impact factor: 3.452

10.  Grifola frondosa water extract alleviates intestinal inflammation by suppressing TNF-alpha production and its signaling.

Authors:  Jong Suk Lee; Su Young Park; Dinesh Thapa; Mi Kyoung Choi; Ill Min Chung; Young Joon Park; Chul Soon Yong; Han Gon Choi; Jung Ae Kim
Journal:  Exp Mol Med       Date:  2010-02-28       Impact factor: 8.718

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.